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Abstract
Bladder cancer is the 10th most common cancer worldwide. For muscle- invasive blad-
der cancer (MIBC), treatment includes radical cystectomy, radiotherapy, and chemo-
therapy; however, the outcome is generally poor. For non– muscle- invasive bladder 
cancer (NMIBC), tumor recurrence is common. There is an urgent need for more ef-
fective and less harmful therapeutic approaches. Here, bladder cancer cell metabolic 
reprogramming to rely on aerobic glycolysis (the Warburg effect) and expression of 
associated molecular therapeutic targets by bladder cancer cells of different stages 
and grades, and in freshly resected clinical tissue, is investigated. Importantly, analy-
ses indicate that the Warburg effect is a feature of both NMIBCs and MIBCs. In two 
in vitro inducible epithelial- mesenchymal transition (EMT) bladder cancer models, 
EMT stimulation correlated with increased lactate production, the end product of 
aerobic glycolysis. Protein levels of lactate dehydrogenase A (LDH- A), which pro-
motes pyruvate enzymatic reduction to lactate, were higher in most bladder cancer 
cell lines (compared with LDH- B, which catalyzes the reverse reaction), but the levels 
did not closely correlate with aerobic glycolysis rates. Although LDH- A is expressed 
in normal urothelial cells, LDH- A knockdown by RNAi selectively induced urothe-
lial cancer cell apoptotic death, whereas normal cells were unaffected— identifying 
LDH- A as a cancer- selective therapeutic target for bladder cancers. LDH- A and other 
potential therapeutic targets (MCT4 and GLUT1) were expressed in patient clinical 
specimens; however, positive staining varied in different areas of sections and with 
distance from a blood vessel. This intratumoral heterogeneity has important thera-
peutic implications and indicates the possibility of tumor cell metabolic coupling.
K E Y W O R D S
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1  | INTRODUC TION
In 2018, there were an estimated 200 000 deaths worldwide from 
bladder cancer.1 A total of 25% of bladder cancer patients present 
with muscle- invasive disease (MIBC), for which treatment includes 
radical cystectomy, radiotherapy, and/or platinum- based chemo-
therapy.2 For patients with metastatic disease, median survival is 
less than 1 year. For the 75% of patients diagnosed with non– muscle- 
invasive bladder cancer (NMIBC), tumor recurrence is common, and 
regular disease monitoring by cystoscopy is required because high- 
grade tumors have a high risk of progression to MIBC.3 As well as 
impacting on patient quality of life, this has a significant cost burden 
for health providers. Until the recent FDA approval of the Fibroblast 
Growth Factor Receptor (FGFR) inhibitor erdafitinib and the immune 
checkpoint inhibitors pembrolizumab and atezolizumab, treatments 
for bladder cancer had not changed significantly for several de-
cades.4 While these therapies are showing very promising effects 
in some patients, there is little or no improved response in others,4 
and there remains a significant need for novel and more effective 
treatments for both MIBCs and NMIBCs.5
Alterations in the metabolism of cancer cells compared with 
normal, healthy cells are an emerging hallmark of most, if not all, 
cancers.6,7 Following on from the discovery of oncogenic driver mu-
tations in isocitrate dehydrogenase (IDH) in acute myeloid leukemia 
(AML) and low- grade gliomas, two selective mutant IDH inhibitors 
ivosidenib and enasidenib have now been FDA- approved for treat-
ment of IDH- mutant AML.8 There is considerable interest in the 
opportunities that cancer- associated metabolic reprogramming may 
provide for targeted therapies that have fewer side effects than 
traditional cytotoxic chemotherapy.9- 12 Apart from targeting IDH- 
mutant cancers, a number of other promising metabolic targets have 
been identified by in vitro and in vivo preclinical studies in different 
tumor types and genetic backgrounds.10- 13
Among different types of metabolic reprogramming that cancer 
cells may undergo, many cancer cells heavily depend upon glycolysis 
even in the presence of oxygen both for the generation of ATP and 
for macromolecule precursors that are required to support cancer 
cell growth and division.7,14 This phenomenon of aerobic glycol-
ysis, otherwise known as the Warburg effect, is directly linked to 
specific oncogene activation and tumor suppressor loss.15- 17 While 
metabolic reprogramming is oncogene driven, it is generally poorly 
understood how different combinations of genetic lesions integrate 
to confer a particular metabolic preference or dependency, and the 
direct oncogenic mutation of metabolic enzymes as seen with IDH 
is rare.14 There is also growing evidence of the importance of non-
genetic, cell- extrinsic factors that also impact upon the metabolic 
phenotype of cancer cells.14,18
While some cancer cell metabolic alterations are neutral for 
tumor growth, others are tumor enabling.14 The Warburg effect 
has been shown to be important for both tumor progression and 
maintenance and to contribute to cell transformation.19- 21 Several 
enzymes directly involved in the Warburg effect, or its promotion, 
are essential for the survival of certain cancer cells, but importantly 
they appear to be dispensable in noncancer cells indicating a likely 
therapeutic window.19- 24
The purpose of this study was to investigate whether bladder 
cancers show the Warburg effect with the longer- term goal that, 
if so, this may enable the development of new targeted therapies 
against bladder cancers. Given the heavier mutational signature of 
MIBCs,25 which includes genes associated with the Warburg effect, 
it was hypothesized that this would be a prominent feature of MIBCs 
but perhaps not of NMIBCs. The expression levels of key enzymes 
and transporters involved in the Warburg effect were also evaluated 
as potential therapeutic targets for further investigation.
2  | MATERIAL S AND METHODS
2.1 | Cell lines and EMT induction
Twenty- three human urothelial carcinoma cell lines were used, 
derived from bladder cancers of different pathological stages and 
grades, as previously described.26- 29 Cell lines and research identi-
fiers (RRID) are detailed in Table S1 with all experiments performed 
using mycoplasma- free cells. Known mutational status of the blad-
der cancer cell lines is shown in Table S2. Cell lines were authenti-
cated by STR profiling28 and within 3 years of the presented cell line 
experiments. Cells were maintained at low passage in antibiotic- free 
growth media, with all experiments conducted within 10 passages of 
authentication. Normal human urothelial cells (NHUCs) were derived 
from urothelium stripped from human ureters obtained at nephrec-
tomy and were maintained in basal keratinocyte growth medium 2 
(C20211, Promocell) containing growth factor supplements, 90 µM 
CaCl2, and 30 ng/ml cholera toxin (Sigma- Aldrich).
30 Telomerase- 
immortalized (TERT) NHUCs (RRID CVCL_JX41) were also utilized.27 
For EMT induction in FGFR1- transduced 94- 10 urothelial carci-
noma cells and in endogenously FGFR1- expressing J82 cells, cells 
were treated with FGF2 (10 ng/mL) or heparin (10 µg/mL) and FGF2 
(10 ng/mL) for 72 hours.31 Further details of treatment of transduced 
and transfected cell lines can be found in Supplementary Methods.
2.2 | Metabolic analyses
Rates of cellular glucose consumption and lactate production 
were determined by quantification of changes in glucose and 
lactate levels in the culture media of cells over time using com-
mercially available assays (Biovision Inc; #K607 [lactate]; #K606 
[glucose]) as previously described.22 These were determined for 
cell lines in log phase growth at ~70% confluence with levels of lac-
tate released into the media or glucose consumed assayed over a 
6- 8- hour period. Cell counts were performed using a Z2 Coulter 
analyzer (Beckman Coulter Ltd) at the assay endpoint. Rates of lac-
tate released or glucose consumed were normalized to cell num-
ber and were determined from a minimum of three independent 
experiments. Cellular oxygen consumption was determined using 
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a Clark- type oxygen electrode (Oxytherm, Hansatech Instruments 
Ltd). Oxygen consumption rates were measured over a 20- minute 
linear period and were normalized to cell number as described.22 
To determine the contribution of mitochondrial oxidative phos-
phorylation (OXPHOS) to cellular oxygen consumption rates, cells 
were treated with 1 µmol/L of the mitochondrial complex I inhibitor 
rotenone to inhibit oxidative phosphorylation. The oxidative meta-
bolic reserve of cell lines was determined using an XFp metabolic 
analyzer (Agilent) and calculation of the maximal increase in oxygen 
consumption rate above basal rates following exposure to a range 
of concentrations of uncoupling agent FCCP (0.125- 2 µmol/L; Cell 
Mito Stress Assay [Agilent]).32
2.3 | Real- time quantitative reverse transcription 
PCR (qRT- PCR)
Total RNA was isolated from cells using an RNeasy mini kit (Qiagen) 
and quantitated by UV spectroscopy as described.33 For real- time 
qRT- PCR, 50 ng of total RNA were used per reaction with Quantitect 
SYBRGreen RT- PCR kit (Qiagen). LDH- A– and LDH- B– specific prim-
ers and cycling conditions were as described.22
2.4 | Gene expression array profiling
Whole- genome expression profiling was performed using GeneChip 
Human Genome U133 Plus 2.0 Arrays (Affymetrix) of total RNA 
from the panel of bladder cancer cell lines (Hurst et al, manuscript 
in preparation). mRNA levels for pyruvate dehydrogenase kinases 
(PDKs) 1- 4 are presented in Figure S4. Results are shown for two dif-
ferent mRNA probe sets for each PDK. Affymetrix probe set identi-
fiers are as follows: PDK1 probe 1: 206686_at, probe 2: 226452_at; 
PDK2 probe 1: 202590_s_at, probe 2: 213724_s_at; PDK3 probe 1: 
206348_s_at, probe 2: 221957_at; PDK4 probe 1: 205960_at, probe 
2: 225207_at.
2.5 | Immunoblotting
Cell lysates were prepared as described34 and protein concentra-
tions determined by the BCA assay. Equivalent protein amounts 
were resolved by SDS- PAGE and electroblotted onto nitrocellulose. 
Primary antibodies were: anti- LDH (Epitomics; antibody detects 
both LDH- A (lower band) and LDH- B (upper band) and has been 
verified for its specificity by RNAi),22 anti- phosphorylated Y10 LDH- 
A,35 anti- aurora A and anti- E- cadherin (Cell Signaling Technology), 
anti- PDH- E1a (Abcam), anti- phosphorylated S293 PDH- E1a (Novus 
Biologics), anti- phosphoERK, anti- ERK and anti- FGFR3 clone B9 
(Santa Cruz Biotechnology), and anti- actin (Chemicon International). 
Quantification of protein bands was done by densitometry analysis 
using Image J software (https://imagej.nih.gov) with levels normal-
ized relative to actin as a loading control.
2.6 | siRNA transfection, LDH inhibition, and 
apoptotic quantification
NHUC, 97- 7, RT112, UMUC3, and J82 cells were transiently trans-
fected with siRNAs 24 hours post seeding by formulating HPLC- 
purified synthetic siRNAs into liposomes using oligofectamine 
(Invitrogen) as previously described.22,33,36 LDH- A, LDH- B, and 
SIRT1 siRNA sequences have been previously validated as de-
scribed.22 Representative phase contrast cell images were taken 
72 hours post transfection, and protein lysates were prepared to 
confirm target protein knockdown. For quantification of apoptotic 
cell death, harvested cells were stained with annexin V and propid-
ium iodide for 15 minutes at 37°C and analyzed by image cytom-
etry as previously described.32 Other cell lines were treated with the 
LDH inhibitor NHI- 222 (15 μmol/L, Sigma) for 48 hours, and effects 
on cell number were compared with vehicle control– treated cells.
2.7 | Patient tissue samples and 
immunohistochemistry
Freshly resected patient tissue samples were obtained from transure-
thral resection samples with the approval of the Leeds East Research 
Ethics Committee and informed patient consent. Specimens were 
weighed on parafilm, washed in fresh DMEM to remove residual 
lactate, and then cultured overnight at 37°C in 5% CO2 in a small 
volume of fresh DMEM containing 10% FBS. A small volume of cul-
ture medium was removed after 4 hours and after overnight culture 
for determination of lactate levels as described.22 The specimens 
were histologically graded and staged according to the 1973 World 
Health Organization recommendations and TNM classification by 
a trained pathologist. For immunohistochemistry, serial sections of 
fixed tissue specimens were blocked following antigen retrieval and 
then stained for target antigens using standard IHC methodology 
as previously described.37 Antibodies used were: GLUT1 (ab15309, 
Abcam), LDH- A (19987- 1- AP, Proteintech), MCT4 (H90, Santa Cruz 
Biotechnology), and MCT1 (AB3538P, Merck Millipore). Total RNA 
from a panel of 263 urothelial tumors was analyzed for mRNA 
expression levels of LDH- A, LDH- B, GLUT1, MCT4, and MCT1 
(Supplementary Methods) (Hurst et al, manuscript in revision).
3  | RESULTS
3.1 | Warburg effect occurrence in bladder cancer 
cell lines derived from stage Ta- T4 tumors
The Warburg effect is defined as the cellular metabolism of glucose 
to lactate in the presence of oxygen.10,38 Analysis of extracellular 
lactate revealed that all 23 human bladder cancer cell lines tested 
performed aerobic glycolysis with rates of cellular lactate release dif-
fering up to ~8- fold across the cell line panel (Figure 1A). Proliferating 
NHUC in culture also released lactate (Figure 1A, green dotted line) 
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consistent with other studies showing that proliferating normal cells 
use aerobic glycolysis to support their growth.39 However, in conflu-
ent NHUC, which is more representative of nonproliferative, differ-
entiated tissue, rates of lactate release were halved (Figure 1A, red 
dotted line).
Rates of cellular glucose consumption were also determined 
(Figure 1B) because lactate can also be generated by glutaminoly-
sis.40 The ratio of cellular rate of lactate release to that of glucose 
consumption was close to 2:1 for the majority of the cell lines 
(Figure 1C), consistent with lactate generation by aerobic glycolysis 
(this generates two molecules of lactate per molecule of glucose 
consumed). Several of the cell lines (eg, 639V, CAL29, BTC909, 97- 7) 
showed a lactate to glucose ratio greater than 2:1 suggesting some 
lactate generation by glutaminolysis.
Clustering of the cell lines based on the grade and stage of 
the tumors from which they were derived (Table S1; Ta and T1 are 
NMIBC; ≥T2 are MIBC) failed to indicate any statistically significant 
correlations with rates of cellular lactate release (Figure 1D). Cell 
clustering based on TP53 mutational status was also performed, as 
loss of p53 tumor suppressor function is reported to promote the 
F I G U R E  1   Aerobic glycolysis of bladder cancer cell lines. A, Rate of cellular lactate release into the culture media of the indicated 
bladder cancer cell lines (nmoles of lactate released into the cell culture media per 106 cells per hour). Values presented represent the 
mean ± SD from a minimum of three independent experiments. Green dotted line represents rate of lactate release by proliferating normal 
human urothelial cells (NHUC), and the red dotted line represents rate of lactate release by confluent NHUC. B, Rate of cellular glucose 
consumption from the culture media of the indicated bladder cancer cell lines (nmoles of glucose consumed per 106 cells per hour). Values 
presented represent the mean ± SD from a minimum of three independent experiments. C, Ratio of the rate of lactate release to the rate of 
glucose consumption. The ratios are calculated from the mean rates shown in (A) and (B), respectively. Dotted line indicates two molecules 
of lactate released per glucose consumed. D, Box and whisker plot showing the median, mean (x), and minimum and maximum rates of 
cellular lactate release by cell lines clustered by grade (left) or stage (right). E, Box and whisker plot showing the median, mean (x), and 
minimum and maximum rates of cellular lactate release by cell lines clustered by p53 status. F, Box and whisker plot showing the median, 
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Warburg effect;16 however, no correlation was observed with cel-
lular rates of lactate release (Figure 1E). Another common genetic 
lesion in bladder cancers associated with the Warburg effect is on-
cogenic mutation of RAS genes.15,17 Interestingly, median and mean 
rates of cellular lactate release were higher in the mutant Ras cell 
cluster (P = .075, Figure 1F).
In addition to mutation of TP53 and RAS genes, a high proportion 
of urothelial carcinomas show upregulation of FGFR1 signalling,41 
and activating mutations in FGFR3 are frequently found in Ta bladder 
cancers.41,42 Interestingly, FGFR1 has been reported to phosphor-
ylate the glycolytic enzyme LDH- A at Y10 and enhance its activity 
in a number of different cancer types.35 It was therefore assessed 
whether increased FGFR1 or FGFR3 signaling in bladder cancers 
has any effect on the phosphorylation of LDH- A or rates of cellular 
lactate production. Using complementary knockdown and overex-
pression approaches, no effects were observed either on LDH- A 
phosphorylation or lactate release (Figure S1). Cell line clustering 
based on FGFR3 mutational status showed that mean and median 
rates of lactate release were both lower in the mutated FGFR3 cell 
cluster, but no statistically significant correlation was observed 
(Figure S1G).
3.2 | Cellular oxygen consumption rates are 
independent of rates of lactate release
Cellular oxidative metabolism was assessed through quantification 
of oxygen consumption rates for fourteen of the bladder cancer cell 
lines (Figure 2A). It was hypothesized that cell lines with the high-
est rates of lactate release may show reduced levels of oxidative 
metabolism and vice versa, consistent with the notion of a meta-
bolic switch away from glucose oxidation and OXPHOS toward gly-
colysis.43 For RT112 and RT4 cells, which show the lowest rates of 
lactate release (Figure 1A), this notion loosely applies with these 
two cell lines having a much higher ratio of oxygen consumption 
to lactate release (Figure 2B) or glucose consumption (Figure S2). 
However, considering all the cell lines analyzed, there was no inverse 
correlation of oxygen consumption rates either with lactate release 
(Figure 2C) or glucose consumption (Figure 2D). Wild- type p53, via 
SCO2, promotes OXPHOS;
44 however, there was no correlation with 
cellular p53 or Ras status or with cell line tumor grade (Figure 2E- G). 
Treatment with mitochondrial complex I inhibitor rotenone45 inhib-
ited oxygen consumption by ~75%- 96% in the four cell lines tested 
(Figure S2B) indicating that the majority of oxygen consumption in 
these cells is due to OXPHOS rather than fatty acid oxidation.
3.3 | mRNA and protein expression of key enzymes 
involved in the Warburg effect
The enzyme lactate dehydrogenase which is composed of LDH- A 
and/or LDH- B subunits, catalyzes the reduction of pyruvate to 
lactate, the last step of aerobic glycolysis. While predominance of 
LDH- A subunits over LDH- B in the LDH tetrameric complex pro-
motes pyruvate reduction to lactate, LDH- B typically favors the re-
verse reaction.46- 48 Expression of LDH- A and LDH- B mRNA differed 
across the 23 bladder cancer cell lines ~17- fold and ~64- fold, re-
spectively, indicating considerable heterogeneity in their expression 
(Figure S3A,B). The relative expression of LDH- A compared with 
LDH- B, which is predicted to influence the directionality of pyru-
vate/lactate interconversion, varied as much as 52- fold across the 
cell line panel (Figure S3C). Relative to RT112 cells, which showed 
the lowest rate of lactate release of the bladder cancer cell lines, 
most of the cell lines expressed increased LDH- A mRNA relative to 
LDH- B, consistent with increasing rates of cellular lactate release 
(Figure S3D).
Similar to mRNA levels, protein expression of LDH- A and LDH- B 
varied both in absolute expression levels and in the relative levels of 
LDH- A and LDH- B across the cell line panel (Figure 3A). mRNA and 
protein levels of LDH- A and LDH- B within individual cell lines were 
only partially correlated, consistent with post- transcriptional regu-
lation of gene expression (Figure 3B,C). LDH- A/LDH- B mRNA and 
protein ratios were positively correlated (R2 = .7809) (Figure 3D). 
Analysis of LDH- A/LDH- B protein ratio as a function of cellular lac-
tate release rate showed that only seven of the 23 cell lines express 
more LDH- B protein than LDH- A, and that these were among the 
slowest lactate producers (Figure 3E). However, there was no pos-
itive linear correlation between LDH- A/LDH- B protein ratio of cell 
lines and their cellular lactate release rates (Figure 3E).
The Warburg effect is also promoted by inhibition of pyruvate 
entry into the TCA cycle through the phosphorylation and inactiva-
tion of pyruvate dehydrogenase (PDH) by PDKs 1- 4.38,49 Like LDH- A 
and LDH- B, mRNA expression of PDKs 1- 4 differed considerably be-
tween cell lines (Figure S4), and phosphorylated PDH levels (PDHP) 
similarly varied (Figure 3A). Analysis of the ratio of PDHP to total 
PDH failed to show a clear correlation with cellular rates of lactate 
release (Figure 3F). These expression results (LDH, PDHP) highlight 
the complexity of regulation of the Warburg effect and the limita-
tions of using a surrogate expression marker and indicate the need 
to measure metabolic flux directly for an accurate readout of the 
magnitude of any Warburg effect.
3.4 | LDH- A silencing impairs growth and survival of 
bladder cancer cell lines
As LDH- A was detectable in all of the bladder cancer cell lines, albeit 
at different expression levels (Figure 3A), the effects of its depletion by 
RNAi were analyzed. Studies in other cancer types have shown LDH- A 
dependency.19,20,22 Using a previously validated LDH- A siRNA,22 im-
munoblots indicated selective depletion of LDH- A protein (Figure 4A; 
NHUC and RT112 LDH blots are overexposed relative to the 97- 7 and 
UMUC3 blots for ease of comparison of knockdown levels). LDH- A 
silencing had no discernible effect on NHUCs (Figure 4B). In bladder 
cancer cell lines (97- 7: highest rate of lactate release; RT112: lowest 
rate of lactate release [Figure 1A]; UMUC3; and J82 cells), cell numbers 
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were significantly reduced by LDH- A depletion which correlated with 
increased apoptotic cell death (Figure 4B,C; Figure S5). Unexpectedly, in 
J82 cells LDH- B silencing induced higher levels of apoptosis than LDH- A 
silencing (Figure S5). Interestingly, further preliminary investigation 
showed that J82 cells express Aurora A kinase (Figure S5), which has re-
cently been shown to phosphorylate LDH- B resulting in LDH- B promot-
ing aerobic glycolysis.48 Against HT1197 and HT1376 bladder cancer 
cells, LDH inhibitor NHI- 222 adversely affected cell growth compared 
with normal urothelial cells and resulted in a ~2.5- fold increase in the 
proportion of late- stage apoptotic cells in the HT1376 cells (Figure S5).
Further metabolic analyses in several of the bladder cancer cell 
lines show a lack of any, or little, oxidative metabolic reserve com-
pared with normal urothelial cells (Figure S6). This suggests that 
while normal urothelial cells may be able to metabolically compen-
sate to targeting of aerobic glycolysis (eg, via LDH- A), the bladder 
cancer cell lines have little oxidative metabolic reserve to be able to 
energetically compensate to sustain their growth and survival.
3.5 | Cellular lactate production is increased in 
response to FGFR1- induced EMT
Ectopic expression and activation of FGFR1 in the urothelial carcinoma 
cell line 94- 10 induces epithelial- mesenchymal transition (EMT).31 As 
increased extracellular lactate has been reported to promote loss of 
cell- cell adhesion that is important for EMT and cancer cell migration 
through extracellular acidification,50- 52 it was investigated what effect 
EMT induction via FGFR1 had on cellular lactate production. FGFR1 
activation in transfected 94- 10 cells, by FGF2, or heparin and FGF2,31 
induced ERK phosphorylation, which is downstream of FGFR1 signaling, 
loss of E- cadherin (Figure 5A), and a change in cell morphology from epi-
thelial to mesenchymal- like (Figure 5B). Significantly, the cells induced 
to undergo EMT also displayed increased rates of lactate production 
(Figure 5C, P < .001). Similar results were also observed in J82 cells in-
duced to undergo EMT (Figure S7). Future studies will investigate this 
further and the potential of targeting lactate release to suppress EMT.
F I G U R E  2   Oxygen consumption 
rates of bladder cancer cell lines are 
independent of aerobic glycolysis and 
cellular rates of lactate production. A, 
Rate of cellular oxygen consumption of 
the indicated human bladder cancer cell 
lines (nmoles of oxygen consumed per 
106 cells per minute). Values presented 
represent the mean ± SD from three 
independent experiments. Cell lines are 
ordered from left to right on the basis of 
cellular lactate release (low to high rate 
of lactate release). B, Ratio of the rate 
of cellular oxygen consumption to the 
rate of cellular lactate release for the 
indicated human bladder cancer cell lines. 
The ratios are calculated from the mean 
rates shown in Figure 2A (O2 consumed) 
and Figure 1A (lactate released). Scatter 
plots of cellular oxygen consumption rate 
against the rate of cellular lactate release 
(C), or glucose consumption rate (D) with 
the mean rates for each individual cell 
line indicated by a black circle. Box and 
whisker plots showing the median, mean 
(x), and minimum and maximum rates of 
cell line oxygen consumption following 
cell line clustering by grade (E), p53 status 
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3.6 | Lactate release by freshly resected Ta, 
T1, and T2 bladder cancer tissue and heterogeneous 
intratumoral expression of key enzymes and 
transporters important for the Warburg effect
To assess whether in vitro cell line observations of the Warburg ef-
fect are relevant in a clinical setting, freshly resected bladder cancer 
tissue was analyzed for lactate release. All the resected bladder can-
cer tissues (Ta, T1, T2) released lactate into the cell culture media 
(Figure 6A). Ta clinical specimens displayed higher rates of lactate 
release than T1 or T2 specimens (P < .05 and P < .01) although the 
number of specimens analyzed of different stages is low, and this 
should therefore be regarded as preliminary data (Figure 6B). Serial 
sections of tissue specimens analyzed for lactate release were as-
sessed for expression of potential therapeutic targets linked to the 
Warburg effect (Figure 6C). Positive cytoplasmic staining was ob-
served for LDH- A in Ta, T1, and T2 specimens. For glucose trans-
porter GLUT1 and lactate export transporter MCT4, membranous 
and/or cytoplasmic staining was obtained. Expression of all three 
potential targets (LDH- A, MCT4, GLUT1) was heterogeneous across 
sections. For example, in the T1 G3 “2165” specimen (Figure 6C), 
increased expression and colocalization of LDH- A, GLUT1, and 
MCT4 are evident further away from a blood vessel, which is con-
sistent with reduced oxygen supply to these cells and increased de-
pendency on aerobic glycolysis. Similar heterogeneous patterns of 
F I G U R E  3   Protein expression of LDH- A, LDH- B, and phosphorylated pyruvate dehydrogenase (PDH) and correlation analysis with cell 
line rates of extracellular lactate release. A, Immunoblots showing relative protein expression levels of LDH- A, LDH- B, phosphorylated PDH 
(S293 PDH- E1a), and total PDH in the indicated bladder cell lines. Actin was used as a loading control with equivalent exposures (normalized to 
RT112) for all cell line panels. Correlation analysis of cell line mRNA and protein levels for LDH- A (B) and LDH- B (C). Mean value for each cell 
line is represented by a black circle. D, Scatter plot of cell line LDH- A/LDH- B mRNA ratio relative to LDH- A/LDH- B protein ratio for each cell 
line. Mean value for each cell line is represented by a black circle; R2 as indicated. E, F, Scatter plots of cell line LDH- A/LDH- B protein ratios and 
PDHP/PDH protein ratios relative to the mean rate of cellular lactate release (Figure 1A), with each individual cell line represented by a black or 
green circle. For the LDH- A/LDH- B protein ratio scatter plot, cell lines above the horizontal red dotted line express more LDH- A protein relative 
to LDH- B. PDHP/PDH total protein ratio is expressed relative to the LUCC8 cell line which showed the highest proportion of phosphorylated 
PDH relative to total PDH levels (LUCC8 PDHP/PDH ratio arbitrarily set at 1). Cell lines within the two horizontal red dotted lines in (F) 
represent cell lines with ≥50% of total PDH being phosphorylated at S293 assuming 100% phosphorylation of LUCC8 total PDH. Green circles 
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expression were also observed in the other specimens with some 
areas of sections showing only weak positive staining for these tar-
gets (Figure 6C). Staining for the lactate import transporter MCT153 
was mostly negative; however, a small number of cells within sec-
tions did positively stain for MCT1 (eg, T2 G3 “2143” specimen; 
Figure 6C). This raises the possibility of metabolic coupling between 
bladder cancer cells in the context of the pathophysiological tumor 
microenvironment (TME); for example, glycolytic cancer cells ex-
porting lactate that is imported by MCT1- expressing cancer cells for 
lactate- fueled OXPHOS.
A panel of 263 urothelial tumors was further analyzed according to 
stage for mRNA expression of Warburg effect– associated putative tar-
gets LDH- A, GLUT1, and lactate export transporter MCT4 as well as 
for LDH- B and lactate import transporter MCT1 (Figure 7). Mean and 
median LDH- A expression was higher in MIBCs than Ta and T1 tumors, 
and MIBCs showed an increased LDH- A/LDH- B ratio. However, GLUT1 
expression was higher in Ta tumors, while there was no significant differ-
ence in expression of lactate export transporter MCT4 across the tumor 
stages (Figure 7). Overall, the analyses do not clearly indicate predomi-
nance of the Warburg effect in any tumor stage but rather that all have 
F I G U R E  4   LDH- A knockdown 
induces apoptotic cell death of bladder 
cancer cell lines but not of normal 
human urothelial cells. A, Immunoblots 
showing selective depletion of LDH- A 
protein by LDH- A siRNA in the indicated 
cell lines and effects of LDH- B siRNA 
at 72 h following siRNA transfection. 
LDH- A/LDH- B blots for normal human 
urothelial cells (NHUC) and RT112 bladder 
cancer cells are overexposed relative to 
the 97- 7 and UMUC3 blots in order to 
obtain similar LDH- A/B protein levels in 
control- transfected cells (no siRNA) for 
all three lines to facilitate comparison of 
extent of LDH- A knockdown between 
the cell lines. Actin was used as a loading 
control. As a positive control for cell 
death induction in NHUC, these cells 
were additionally treated with SIRT1 
siRNA. B, Representative phase contrast 
images of 97- 7, RT112, and UMUC3 
human bladder cancer cells and of normal 
human urothelial cells (NHUCs) 72 h post 
transfection with the indicated siRNAs. 
C, Quantification of apoptotic cell death 
induced by LDH- A and LDH- B siRNAs 
72 h post transfection as determined by 
the proportion of annexin V– positive cells; 
values are expressed as a fold change in 
the proportion of annexin V– positive cells 
relative to background levels in control 
cells
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upregulation, suggesting that this may be an early requirement during 
tumor development. Expression of lactate import transporter MCT1 was 
modestly increased in T1 and some MIBCs compared with Ta, which may 
account for decreased lactate release in some specimens analyzed com-
pared with Ta (Figure 6A) and is further supportive of metabolic coupling 
in the TME. Figure S8 shows association of expression of the different 
putative targets with patient overall survival following analysis of the 
publicly available urothelial cancer TCGA dataset (n = 408; R2 Genomics 
Analysis Platform, http://r2.amc.nl) with higher expression generally as-
sociated with worse overall survival (except for LDH- B).
4  | DISCUSSION
Treatments and outcomes for both NMIBCs and MIBCs have 
changed little over the past few decades, and there is an urgent need 
for new therapeutic approaches. Recent studies have identified sev-
eral distinct genomic subtypes of both NMIBC and MIBC based 
on their mutational and gene copy number signatures.25,37 It is ex-
pected that this will facilitate the development of targeted therapies 
against the specific subtypes. A key finding from this study is that 
aerobic glycolysis (the Warburg effect) is a feature of both NMIBCs 
and MIBCs (Figures 1, 6, and 7) indicating opportunity to develop 
targeted therapies exploiting this for both NMIBC and MIBC.
The Warburg effect in NMIBC is consistent with the recent iden-
tification of a NMIBC genomic subtype that is characterized by loss 
of chromosome region 9q and tumor suppressor TSC1 and upreg-
ulated mTORC1 signaling, which would be predicted to stimulate 
aerobic glycolysis.37 Genetic alterations to a number of different 
tumor suppressor genes and proto- oncogenes are known to stimu-
late aerobic glycolysis.15- 17 This includes loss of p53 and TSC1 tumor 
suppressor functions and activating mutations in PIK3CA, RAS, and 
F I G U R E  5   Enhanced rates of lactate 
release following epithelial mesenchymal 
transition (EMT) induction in an in vitro 
FGFR1- inducible bladder cancer model 
of EMT. A, Immunoblots showing the 
induction of FGFR1 signaling in FGFR1- 
expressing 94- 10 human bladder cancer 
cells by FGF2, or FGF2 plus heparin, as 
indicated by increased phosphorylated 
ERK and increased EMT as indicated 
by decreased E- cadherin expression. 
Effect of FGFR1- induced EMT on LDH- A, 
LDH- B, and LDH- A phosphorylation levels 
are also shown. B, Phase contrast images 
showing the induction of a mesenchymal- 
like morphology (indicated by black 
arrows) following treatment of FGFR1- 
expressing 94- 10 human bladder cancer 
cells with FGF2 or FGF2 plus heparin, 
consistent with EMT. C, Effect of EMT 
induction on the rate of cellular lactate 
release (nmoles lactate released/106 cells/
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AKT, all of which are found in different bladder cancer subtypes. 
Consistent with this, aerobic glycolysis, as indicated by extracellular 
lactate release, was evident in all bladder cancer cell lines analyzed 
(Figure 1) with only RT112 cells (lowest rate of cellular lactate re-
lease, Figure 1) lacking a mutation in any of these genes (Table S2). It 
is likely that this metabolic switch occurs via different genetic routes 
in different cell lines, which may account for the wide variation in 
rates of extracellular lactate release observed across the panel, with 
different integrating promoting (and inhibitory) contributions by dif-
ferent combinations of genetic mutations. In support of this, cell line 
clustering based on mutation status of three key genes commonly 
mutated in bladder cancers, TP53, RAS, and FGFR3, failed to indicate 
any significant correlation with rates of lactate release. Interestingly, 
median and mean lactate release rates were higher in the mutant Ras 
cell cluster, and although this was not statistically significant, it indi-
cates a positive trend that is consistent with mutant Ras promoting 
aerobic glycolysis in other cancers. It is also noteworthy that the two 
bladder cancer cell lines with the lowest rate of lactate release and 
largest ratio of oxygen consumed to lactate released (indicating in-
creased OXPHOS relative to aerobic glycolysis), RT112 and RT4, har-
bor FGFR3- TACC3 genetic fusions54 (Table S2). The FGFR3- TACC3 
oncogenic fusion has recently been reported to increase OXPHOS 
and mitochondrial biogenesis.55
It is a commonly held view that cancer cells undergo a metabolic 
switch from OXPHOS to aerobic glycolysis.10,43 Importantly, met-
abolic analyses of bladder cancer cell lines here show that cellular 
lactate release rates and oxygen consumption rates do not inversely 
correlate (Figure 2). Indeed, there is some indication of a weak pos-
itive correlation (Figure 2C). This supports metabolic analyses of 
tumors in vivo which suggests the metabolic switch involves upreg-
ulation of both aerobic glycolysis and mitochondrial respiration.10
The bladder cancer cell line studies identify for the first time the 
glycolytic enzyme LDH- A as a potential, and cancer- selective, thera-
peutic target for bladder cancers with normal urothelial cells shown 
to be refractory to LDH- A knockdown (Figure 4). Bladder cancer 
cells were shown to have little or no oxidative metabolic reserve to 
compensate for inhibition of aerobic glycolysis (Figure S6). In blad-
der cancer clinical specimens, release of extracellular lactate was 
observed indicating that aerobic glycolysis is a metabolic feature of 
bladder cancer tissue that could potentially be targeted (Figures 6 
and 7). LDH- A as well as other targets linked to the Warburg effect 
(MCT4, GLUT1) are expressed in both NMIBC and MIBC (Figures 6 
F I G U R E  6   Lactate release by freshly 
resected bladder cancer tissue and 
intratumoral heterogeneous expression of 
key targets associated with the Warburg 
effect. A, Mean rate of lactate release 
into fresh growth medium per milligram of 
tumor tissue per hour. Stage and grading 
of tumor tissue as indicated. Freshly 
resected TURBTs were weighed prior to 
overnight (16 h) incubation in 500 µL of 
fresh growth media at 37°C in a 5% CO2 
incubator and determination of levels of 
lactate released into the medium during 
the incubation period (see "Methods” 
section). Four- (or three- ) digit numbers 
indicate anonymized clinical specimen 
identifiers for different patient samples. 
Mean ± SD from three independent 
lactate determinations. B, Box plot of the 
mean rates of cellular lactate release by 
clinical specimens clustered by stage and 
grade, *P < .05, **P < .01, Student's t- test. 
C, Tissue sections of the indicated clinical 
specimens (analyzed in [A] for lactate 
release) that have been immunostained 
for the indicated metabolic targets. 
Representative IHC images are shown; 
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and 7), but protein expression was heterogeneous in IHC sections. 
This intratumoral heterogeneity suggests that some tumor regions 
may be carrying out aerobic glycolysis, whereas others may not. 
This raises the possibility of metabolic symbiosis or coupling be-
tween cancer cells in different regions of the same tumor as was 
first proposed and elegantly demonstrated by Sonveaux and col-
leagues.53,56,57 In support of this in the context of bladder cancers, 
sections showed increased staining for LDH- A, GLUT1, and MCT4 
furthest from blood vessels, consistent with tumor hypoxia and in-
creased dependency on aerobic glycolysis. In contrast, cells nearer 
blood vessels could potentially utilize lactate produced from hypoxic 
cells as a fuel for OXPHOS,53,56,57 and this may account for the rela-
tively low rates of extracellular lactate release shown by the clinical 
specimens compared with the cell lines. The extracellular release 
of lactate, in addition to potentially being utilized as a fuel,53,56,57 
could also potentially facilitate the migration of glycolytic or hypoxic 
bladder cancer cells toward blood vessels or a more favorable en-
vironment.50- 52 In two inducible EMT models, EMT induction, an 
important step in cells becoming more migratory, was positively 
associated with increased extracellular lactate release (Figure 5; 
Figure S7). While further studies are needed to fully understand this, 
it raises the possibility that the targeting of aerobic glycolysis and 
decreased lactate release might also be beneficial as a barrier against 
bladder cancer cell migration and invasion.
In summary, this work identifies aerobic glycolysis as a targeta-
ble feature of both NMIBC and MIBC. Intratumoral heterogeneity 
in expression of potential targets exemplifies the importance of the 
TME as well as cancer cell genetics, with aerobic glycolysis inhibitors 
(eg, LDH- A inhibitors) predicted to be most effective against hypoxic 
regions of tumors. Intratumoral heterogeneity and possible lactate 
shuttling from glycolytic cancer cells to fuel OXPHOS in other can-
cer cells indicates the likely need to use aerobic glycolysis inhibitors 
in combination with other metabolic inhibitors (eg, of OXPHOS) for 
effective therapeutic targeting of bladder cancers. However, the 
option of intravesical delivery to the bladder may enable effective 
metabolic inhibitor combinations unavailable to treat other cancer 
types that would otherwise be toxic with systemic administration.
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